nach oben

Erschienen in:

01.12.2015 | Review

Biologic therapy for refractory scleritis: a new treatment perspective

verfasst von: Tania Sales de Alencar de Fidelix, Luis Antonio Vieira, Denise de Freitas, Virginia Fernandes Moça Trevisani

Erschienen in: International Ophthalmology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Scleritis is an umbrella term for a heterogeneous group of ocular diseases that can be associated with autoimmune or systemic disorders. The purpose of this article was to review the literature regarding the use of biologic drugs to treat refractory scleritis. A search of the MEDLINE, Embase, and LILACS electronic databases was conducted, and the reference lists of published articles were hand-searched. No language filters were used. This search strategy yielded no randomized trials of the use of biologic therapies to treat scleritis; only case reports and retrospective studies were retrieved. These studies suggest that monoclonal antibodies (infliximab and adalimumab) are superior to the soluble TNF receptor fusion protein etanercept for the treatment of scleritis in patients that do not respond to corticosteroids and/or to immunosuppressive treatment. Rituximab seems to be the best option for scleritis associated with vasculitis.

Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P (2013) Scleritis: immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res 35:44–62. doi:10.1016/j.preteyeres.2013.02.004 CrossRefPubMed

Foster CS (2013) Ocular manifestations of the potentially lethal rheumatologic and vasculitic disorders. J Fr Ophtalmol 36:526–532. doi:10.1016/j.jfo.2012.12.004 CrossRefPubMed

Watson PG, Hayreh SS (1976) Scleritis and episcleritis. Br J Ophthalmol 60:163–191PubMedCentralCrossRefPubMed

Kraus CL, Culican SM (2012) Use of biologic agents in ocular manifestations of rheumatic disease. Int J Rheumatol 203819

Okada AA (2005) Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13:335–351CrossRefPubMed

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244–279CrossRefPubMed

Rachitskaya A, Mandelcorn ED, Albini TA (2010) An update on the cause and treatment of scleritis. Curr Opin Ophthalmol 21:463–467. doi:10.1097/ICU.0b013e32833f1060 CrossRefPubMed

Herrera-Esparza R, Avalos-Diaz E (2009) Infliximab treatment in a case of rheumatoid scleromalacia perforans. Reumatismo 61:212–215PubMed

Sen HN, Sangave A, Hammel K, Levy-Clarke G, Nussenblat RB (2009) Infliximab for the treatment of severe scleritis. Can J Ophthalmol 44:e9–e12PubMedCentralCrossRefPubMed

10.

Doctor P, Sultan A, Syed S, Christen W, Bhat P, Foster CS (2010) Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 94:579–583. doi:10.1136/bjo.2008.150961 PubMedCentralCrossRefPubMed

11.

Oh JY, Kim MK, Wee WR (2011) Infliximab for progressive peripheral keratitis in a patient with juvenile rheumatoid arthritis. Jpn J Ophthalmol 55:70–71. doi:10.1007/s10384-010-0889-7 CrossRefPubMed

12.

Jabbarvand M, Fard MA (2010) Infliximab in a patient with refractory necrotizing scleritis associated with relapsing polychondritis. Ocul Immunol Inflamm 18:216–217. doi:10.3109/09273941003624914 CrossRefPubMed

13.

Ashok D, Ayliffe WH, Kiely PD (2005) Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatology (Oxford) 44:950–951. doi:10.1093/rheumatology/keh635 CrossRef

14.

Cazabon S, Over K, Butcher J (2005) The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye (Lond) 19:222–224CrossRef

15.

Murphy C, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D (2004) Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111:352–356CrossRefPubMed

16.

El-Shabrawi Y, Hermann J (2005) Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener’s granulomatosis. Eye (Lond) 19:1017–1018. doi:10.1038/sj.eye.6701712 CrossRef

17.

Atchia II, Kidd CE, Bell RW (2006) Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol 12:291–293. doi:10.1097/01.rhu.0000249766.24780.95 CrossRefPubMed

18.

Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS (2007) Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 125:895–900. doi:10.1001/archopht.125.7.895 CrossRefPubMed

19.

Weiss K, Rieger R, Keitzer R, Pleyer U (2007) Successful infliximab treatment of posterior scleritis in a 13-year-old child refractory to other immunosuppressive. Graefes Arch Clin Exp Ophthalmol 245:1735–1737CrossRefPubMed

20.

Ahn SJ, Oh JY, Kim MK, Wee WR (2009) Treating refractory scleritis with infliximab. Jpn J Ophthalmol 53:286–287. doi:10.1007/s10384-008-0652-5 CrossRefPubMed

21.

Sassa Y, Kawano Y, Yamana T, Mashima T, Ishibashi T (2012) A change in treatment from etanercept to infliximab was effective to control scleritis in a patient with rheumatoid arthritis. Acta Ophthalmol 90:e161–162. doi:10.1111/j.1755-3768.2010.02090.x CrossRefPubMed

22.

Huynh N, Cervantes-Castaneda RA, Bhat P, Gallagher MJ, Foster CS (2008) Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm 16:89–93. doi:10.1080/09273940802023786 CrossRefPubMed

23.

Medina GMA, Domínguez JG, Villaverde GR, Alvarez ER (2010) Infliximab para el tratamento de la escleritis anterior necrosante associada a artritis reumatoide seropositiva. Med Clin (Barc) 134:234–236CrossRef

24.

Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45:252–257. doi:10.1002/1529-0131(200106)45:3<252:AID-ART257>3.0.CO;2-5 CrossRefPubMed

25.

Díaz-Valle D, Sánchez RM, Espartero MCF, Allen DP (2009) Tratamiento de la escleritis anterior difusa refractaria con infliximab. Arch Soc Esp Oftalmol 79:405–408

26.

Restrepo JP, Molina MP (2010) Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 29:559–561. doi:10.1007/s10067-009-1368-8 CrossRefPubMed

27.

Pasut G (2014) Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs 28(Suppl 1):15–23. doi:10.1007/s40259-013-0064-z CrossRef

28.

Tlucek PS, Stone DU (2012) Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea 31:90–91. doi:10.1097/ICO.0b013e318211400a CrossRefPubMed

29.

Le Garrec J, Marcelli C, Mouriaux F (2009) Can tumor necrosis factor inhibitors induce sclero-uveitis? J Fr Ophthalmol 32:511CrossRef

30.

Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, Wendling D, Liote F (2012) Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 39:233–239. doi:10.3899/jrheum.110865 CrossRefPubMed

31.

Benucci M, Manfredi M, Puttini PS, Atzeni F (2010) Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev 9:801–803. doi:10.1016/j.autrev.2010.07.006 CrossRefPubMed

32.

De Vita S, Quartuccio L (2006) Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 5:443–448. doi:10.1016/j.autrev.2006.02.007 CrossRefPubMed

33.

Dörner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G (2009) Current status on B cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 9:82–89CrossRefPubMed

34.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390–1400. doi:10.1002/art.21778 CrossRefPubMed

35.

Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger U, Klareskog L, Kvien TK, Martin-Mola E, Pavelka K (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66:143–150PubMedCentralCrossRefPubMed

36.

Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, Conti V, Ranieri J, Colantuono S, Fognani E, Piluso A, Tinelli C, Zignego AL, Mondelli MU, Fiorilli M, Casato M (2011) A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 10:714–719. doi:10.1016/j.autrev.2011.04.033 CrossRefPubMed

37.

Kong JS, Teuber SS, Gershwin ME (2006) Potential adverse events with biologic response modifiers. Autoimmun Rev 5:471–485. doi:10.1016/j.autrev.2006.02.014 CrossRefPubMed

38.

Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M, Zamudio-Huerta L, López-Colombo A, Cervera R (2009) Use of rituximab in systemic lupus erythematosus: an update. Autoimmun Rev 8:343–348CrossRefPubMed

39.

Conti F, Perricone C, Ceccarelli F, Valesini G (2010) Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 9:716–720. doi:10.1016/j.autrev.2010.07.013 CrossRefPubMed

40.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45:1432–1436. doi:10.1093/rheumatology/kel098 CrossRef

41.

Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540–548. doi:10.1111/j.1365-2796.2005.01494.x CrossRefPubMed

42.

Tobon GJ, Pers JO, Youinou P, Saraux A (2010) B cell-targeted therapies in Sjogren’s syndrome. Autoimmun Rev 9:224–228. doi:10.1016/j.autrev.2009.08.001 CrossRefPubMed

43.

Quartuccio L, Fabris M, Salvin S, Maset M, De Marchi G, De Vita S (2009) Controversies on rituximab therapy in Sjogren syndrome-associated lymphoproliferation. Int J Rheumatol. doi:10.1155/2009/424935 PubMedCentralPubMed

44.

Lim L, Suhler EB, Smith JR (2006) Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 34(4):365–374CrossRefPubMed

45.

Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL (2005) Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann Rheum Dis 64:1087–1088. doi:10.1136/ard.2004.027128 PubMedCentralCrossRefPubMed

46.

Cheung CM, Murray PI, Savage CO (2005) Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol 89:1542. doi:10.1136/bjo.2005.075689 PubMedCentralCrossRefPubMed

47.

Kurz PA, Suhler EB, Choi D, Rosenbaum JT (2009) Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol 93:546–548. doi:10.1136/bjo.2007.133173 CrossRefPubMed

48.

Chauhan S, Kamal A, Thompson RN, Estrach C, Moots RJ (2009) Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 93:984–985CrossRefPubMed

49.

Onal S, Kazokoglu H, Koc A, Yavuz S (2008) Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm 16:230–232. doi:10.1080/09273940802331643 CrossRefPubMed

50.

Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum 60:1540–1547CrossRefPubMed

51.

Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T (2010) Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 18:223–225. doi:10.3109/09273941003739928 CrossRefPubMed

52.

Gómez LMZ, Franco CJV, Foronda JCH, Alzate CFC (2012) Uso de rituximabe en una paciente con escleritis anterior difusa necrotizante asociada a vasculitis con c-ANCA refractaria a immunomoduladores convencionales. Rev Colomb Reumatol 19:183–189

53.

Bogdanic-Werner K, Fernandez-Sanz G, Alejandre Alba N, Ferrer Soldevila P, Romero-Bueno FI, Sanchez-Pernaute O (2013) Rituximab therapy for refractory idiopathic scleritis. Ocul Immunol Inflamm 21:329–332. doi:10.3109/09273948.2013 CrossRefPubMed

54.

Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, Sardos AS, Butler NJ, Smith JR, Rosenbaum JT (2014) Rituximab in the treatment of refractory scleritis and non-infeccious orbitary inflammation: preliminary results from a Phase I/II prospective, randomized, dose-ranging pilot study. JAMA Ophthalmol 132:572–578. doi:10.1001/jamaophthalmol.2013.8179 PubMedCentralCrossRefPubMed

55.

Turchetti G, Smolen JS, Kavanaugh A, Braun J, Pincus T, Bombardieri S (2012) Treat-to-target in rheumatoid arthritis: clinical and pharmacoeconomic considerations. Introduction. Clin Exp Rheumatol 30:S1PubMed

56.

McCluskey P, Wakefield D (1991) Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust N Z J Ophthalmol 19:211–215CrossRefPubMed

57.

Sen HN, Sangave AA, Golgstein DA, Suhler EB, Cunningham D, Vitale S, Nussenblatt RB (2011) A stardardized grading system for scleritis. Ophthalmology 118:768–771PubMedCentralCrossRefPubMed

58.

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ (2005) Updated consensus statement on biological agents, specifically tumor necrosis factor α (TNF α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 64 Suppl 4:iv2-14. doi: 10.1136/ard.2005.044941

59.

Freidlin J, Wong IG, Acharya N (2007) Rituximab treatment for peripheral ulcerative keratitis associated with Wegener’s granulomatosis. Br J Ophthalmol 91:1414. doi:10.1136/bjo.2006.113316 PubMedCentralCrossRefPubMed

60.

Foster CS, Chang PY, Ahmed AR (2010) Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 117:861–869. doi:10.1016/j.ophtha.2009.09.049 CrossRefPubMed

61.

Huerva V, Sanchez MC, Traveset A, Jurjo C, Ruiz A (2010) Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis. Cornea 29:708–710. doi:10.1097/ICO.0b013e3181c296ed PubMed

62.

Beardsley RM, Suhler EB, Rosenbaum JT, Lin P (2013) Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother 14:411–424. doi:10.1517/14656566.2013.772982 PubMedCentralCrossRefPubMed

63.

Onrust SV, Lamb HM, Balfour JA (1999) Rituximab. Drugs 58:79–88CrossRefPubMed

64.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(785–796):e783. doi:10.1016/j.ophtha.2013.09.048

65.

Saw VPJ, Cornelius N, Salama AD, Pusey C, Lightman SL (2008) Infliximab therapy for aggressive Mooren ulceration. Arch Ophthalmol 126:734CrossRefPubMed

66.

Cordero-Coma M, Méndez RS, Blanco AC, Corral AL, Calleja-Antolin S, Morales JMR (2012) Adalimumab for refractory peripheral ulcerative keratitis. J Ophthal Inflamm Infect 2:227–229. doi:10.1007/s12348-012-0080-z CrossRef

67.

Fontana L, Parente G, Neri P, Reta M, Tassinari G (2007) Favourable response to infliximab in a case of bilateral refractory Mooren’s ulcer. Clin Experiment Ophthalmol. 35:871–873. doi:10.1111/j.1442-9071.2007.01609.x CrossRefPubMed

Titel: Biologic therapy for refractory scleritis: a new treatment perspective
verfasst von: Tania Sales de Alencar de Fidelix
Luis Antonio Vieira
Denise de Freitas
Virginia Fernandes Moça Trevisani
Publikationsdatum: 01.12.2015
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 6/2015
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-015-0124-0

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Biologic therapy for refractory scleritis: a new treatment perspective

Abstract

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

A novel Hartman Shack-based topography system: repeatability and agreement for corneal power with Scheimpflug+Placido topographer and rotating prism auto-keratorefractor

Our experience with transcanalicular laser-assisted endoscopic dacryocystorhinostomy (TCLADCR) in patients of chronic dacryocystitis with deviated nasal septum

Lateral eyelid rotation flap: a novel technique for reconstruction of full thickness eyelid defect

Collagen cross-linking in keratoconus in Asian eyes: visual, refractive and confocal microscopy outcomes in a prospective randomized controlled trial

Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India

Macular and retinal nerve fiber thickness in recovered and persistent amblyopia

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde